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Abstract
The field of Regenerative Biology as it applies to Regenerative Medicine is an increasingly expanding
area of research with hopes of providing therapeutic treatments for diseases and/or injuries that
conventional medicines and even new biologic drug therapies cannot effectively treat. Extensive
research in the area of Regenerative Medicine is focused on the development of cells, tissues and
organs for the purpose of restoring function through transplantation. The general belief is that
replacement, repair and restoration of function is best accomplished by cells, tissues or organs that
can perform the appropriate physiologic/metabolic duties better than any mechanical device,
recombinant protein therapeutic or chemical compound. Several strategies are currently being
investigated and include, cell therapies derived from autologous primary cell isolates, cell therapies
derived from established cell lines, cell therapies derived from a variety of stem cells, including bone
marrow/mesenchymal stem cells, cord blood stem cells, embryonic stem cells, as well as cells
tissues and organs from genetically modified animals. This mini-review is not meant to be
exhaustive, but aims to highlight clinical applications for the four areas of research listed above and
will address a few key advances and a few of the hurdles yet to be overcome as the technology and
science improve the likelihood that Regenerative Medicine will become clinically routine.
Introduction
Many diseases and or physical defects due to injury result
in the loss of specialized cells within organ systems and
lead to organ system dysfunction. For example, Parkin-
son's disease results in the progressive loss of dopaminer-
gic neurons within the substantia nigra region of the brain
leading to motor deficits that result in dystonia and dysk-
inesia. Injuries, such as meniscal tears and spinal cord
injury, can also result in the degeneration and loss of tis-
sue leading to physical defects that can affect normal
behavior. Additionally, insulin dependant diabetes melli-
tus (IDDM), multiple sclerosis (MS) and other autoim-
mune disorders lead to a loss of tissue that disrupts
normal metabolism and bodily functions. The potential
to treat these conditions with cell-based therapies holds
promise for tissue/organ repair with the ultimate goal to
regenerate and restore normal function. Several cell types
will be discussed and are defined as; tissue specific differ-
entiated cells, such as chondrocytes; progenitor cells iso-
lated from specific tissues, such as bone marrow stem cells
or neural stem cells; and embryonic stem cells that are
derived from the inner cell mass of the developing blast-
omere.
Autologous Cell Therapy
Tissue specific differentiated autologous cells (as opposed
to autologous progenitor cells, see below) harvested from
an individual, cultured ex vivo to expand, and reintro-
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duced into a second site for repairing damaged tissue with
"self" is ideal from an immunologic perspective. Several
pre-clinical models as well as clinical applications are cur-
rently being explored and include chondrocytes for carti-
lage repair [1-12], keratinocytes and/or dermal fibroblasts
for burn and wound repair [13-17], myocytes for myocar-
dial repair [18-23], retinal pigment epithelial cells for age
related macular degeneration [24-27] and Schwann cell
transplantation to restore myelin in CNS lesions. [28-32].
The two most developed autologous cell therapies that
have advanced from the laboratory to the clinic involve
the repair of cartilage using autologous chondrocytes and
the treatment of burns with autologous cultured keratino-
cytes.
Grande et. al., first demonstrated that autologous
chondrocyte cultures could be utilized to repair articular
cartilage defects in the rabbit knee [11,12]. Subsequently,
this technique has been applied to the clinical treatment
of articular cartilage defects [1,4,7,33] and has now
evolved into an FDA approved therapy supplied by Gen-
zyme Biosurgery http://www.fda.gov/cber/approvltr/
autogen082297L.htm. Genzyme Biosurgery has also
developed an autologous keratinocyte culture procedure
and currently markets Epicel® as a treatment for burn vic-
tims http://www.genzymebiosurgery.com/prod/burn/
gzbx_p_pt_burn.asp. Although repairing "self" with "self"
is attractive and doesn't require immunosuppressive drug
therapy for graft maintenance, there are limitations
related to the harvesting of tissue and expanded tissue cul-
ture. Typically, harvesting the original source tissue from
the patient requires a surgical procedure which minimally
is a biopsy, but could also require a large resection of the
tissue. The concern is causing a second site defect that
leads to pain, discomfort or a deficit that effects behavior,
hopefully to a lesser extent than the original. The ability of
the adult tissue to expand in tissue culture to generate suf-
ficient numbers of cells is also a potential limitation.
Additionally, primary cell cultures can become senescent
or dedifferentiate during the culture period. Another lim-
itation is that this type of therapy is only amenable to tis-
sues that can sustain surgical harvesting and ex vivo
culturing, emphasized by the fact that only two autolo-
gous cell therapies have achieved FDA approval for the
medical market.
Autologous progenitor cells harvested from an individual
and used for "self" tissue repair is also immunologically
ideal. The most widely used source of adult progenitor
cells are derived from bone marrow. The mesenchymal
compartment within the bone marrow has the capacity to
differentiate into many cell and tissue types given the
appropriate growth conditions [34]. Early studies using
bone marrow stromal cells for tissue repair focused on the
repair of bone defects [35] however, more recent studies
have applied bone marrow progenitor cells to repair a
variety damaged tissue types, including cartilage [36-38],
myocardium [39,40], liver [41], spinal cord injury [42-44]
and most recently diabetes [45]. However, these differen-
tiation studies are still in the experimental stage. The
potential to differentiate "self" progenitor cells into a vari-
ety of tissues is extremely promising for the field of Regen-
erative Medicine, however continued experimentation is
necessary to understand the differentiation processes and
to be able to reproducibly guide these cells into the appro-
priate tissue, prior to clinical application.
Autologous peripheral blood or autologous bone marrow
stem cells are currently used clinically, but not from a
commercial stand point. A current search of the FDA web
site http://clinicaltrials.gov resulted in 108 studies involv-
ing autologous peripheral blood or autologous bone mar-
row stem cells as a treatment therapy, 96 of which were
related to cancer treatments. None of the trials are related
to stem cell differentiation followed by transplantation.
Allogeneic Tissues and Cell Lines
The use of allogeneic tissue for transplantation is clinically
routine due to the development of immunosuppressive
drug therapies, such as cyclosporine, FK506 and rapamy-
cin. The use of engineered tissue and specialized cell lines
for the treatment of disease and injury is more recent and
will also require immunosuppression unless engineering
strategies are utilized to make the tissue resistant to
immune destruction or through tissue processing to
reduce immunogenicity. As is the case for autologous cell
therapies, the furthest advances are in the area of connec-
tive tissue replacement, cartilage and skin. [46-48] Cur-
rently, Apligraft® (Organogenesis, Inc) is used as a dermal
replacement for chronic wounds and is composed of neo-
natal foreskin kerotinocytes and dermal fibroblasts [49].
Although earlier studies demonstrated that Langerhan's
cell-free epidermal skin cultures were rejected following
transplantation [50], Apligraft tissue appears to be
uniquely non-immunogenic due to the processing of the
tissue [51,52] and represents an exception to the need for
immunosuppression during allogeneic transplantation. A
similar product, Dermagraft® is also available from Smith
& Nephew.
Another interesting allogeneic cell type harvested from
cadaveric sources for the treatment of Parkinson's disease
are allogeneic cultured retinal pigment epithelial cells that
are encapsulated to provide an immune barrier [53]. Titan
Pharmaceuticals, Inc has advanced this research into the
clinic and is currently conducting a Phase IIb clinical trial
with initial positive results [54].
Allogeneic cell lines are also being developed as a source
of cells for regenerating damaged tissue due to disease.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/102
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The human NT2 cell line was shown to differentiate and
develop into neurons in rodent stroke models [55,56] and
is currently being tested in clinical trials for the treatment
of stroke by Layton Biosciences, Inc [57,58]. Patients
receiving the NT2 cell grafts do receive immunosuppres-
sion to inhibit immune rejection of the graft [57,58].
The development of allogeneic engineered tissues for
commercial purposes has similar limitations as commer-
cial autologous cell therapies with the added complica-
tion of immune rejection. Encapsulation, tissue
processing, tolerance induction and/or genetic modifica-
tion will be necessary unless the patient population is
receptive to and the severity of the disease warrants the use
of immunosuppressive drugs.
Allogeneic stem cells
Allogeneic bone marrow transplantation is used clinically
to treat hematologic disorders and cancer, but as is the
case for autologous bone marrow transplantation, not
from a commercial, tissue engineering standpoint. New
clinical trials are focusing on the use of peripheral blood
stem cells and specific subsets of bone marrow stem cells
for these indications (for example [59,60]). Searching the
FDA clinical trial data base identified 117 trials that utilize
allogeneic stem cells or bone marrow in the treatment
regime. Sorting through those trials, 99 were specific for
stem cell therapy. As for autologous bone marrow or
peripheral blood stem cell therapies, most were for cancer
indications, 84/99. The data base included 9 trials utiliz-
ing allogeneic stem cells for anemia/hematologic disor-
ders, 2 trials are designed to treat metabolic storage
diseases and there are single trials for each of the follow-
ing; Granulomatous Disease, HIV patients not responsive
to highly active antiretroviral therapy, Mycosis Fungoides
and Sezary Syndrome and allogeneic bone marrow rejec-
tion http://clinicaltrials.gov. Virtually all of these thera-
pies are in combination with some form of
immunosuppression and none of the trials are related to
stem cell differentiation followed by transplantation.
The discovery and isolation of neural stem cells from fetal
[61-64] and adult human brain [65,66] is a significant
development in the area of neural cell differentiation that
has led to the possibility of producing specialized cells for
the treatment of neurologic disorders, such as Parkinson's
disease and spinal cord injury. Many groups have studied
the differentiation of neurospheres into neuron, glial, and
astrocyte lineages, however the work from Goldman's
group [66,67] sets a president for selection strategies that
are most relevant to the field of tissue engineering. Nunes,
et. al., and Keyoung et. al., showed that transfected/trans-
duced specific promoter constructs driving green fluores-
cent protein (GFP) can be used to select specific neural
progenitor cells by flow cytometry [66,67]. Expanding on
these techniques could lead to the eventual development
of a commercial application of neural stem cells by repro-
ducibly selecting the desired neural phenotype. Demon-
strating that specific lineages can be selected genetically
with drug selectable or fluorescent expression plasmids
lays the ground work for further selection schemes and
further genetic modifications, such as modifying the
immune response leading to a universally accepted source
of human neural tissue for transplantation.
Although stem cells from adult tissues have more plastic-
ity than originally thought, they typically are limited in
their capacity to generate all possible tissue and cell types.
Stem cells derived from the inner cell mass of the early
embryonic blastocyst (ES cells) can proliferate indefi-
nitely [68] and can give rise to virtually any cell type [69].
The development of human embryonic stem cells [70] has
raised the possibility that an unlimited supply of human
tissue could be generated from ES cells and that these tis-
sues could be used to replace and repair damaged tissue in
any organ system. It should be noted that although these
human cells are referred to as ES cells, they cannot be
qualified as a true "ES cell" which is defined by the ability
to contribute to the germ line during embryonic develop-
ment. ES cells from other species are tested in this manner,
however it is ethically unfeasible with human ES cells.
Having qualified the definition of a human ES cell, several
studies have demonstrated that human ES cells retain the
capacity to differentiate into a variety of tissues, including
neuronal cells, myocytes, adipocytes and hematopoietic
cells [71-77]. The challenge now is to be able to direct dif-
ferentiation or select for the desired phenotype and to
develop these therapies in the absence of immunosup-
pression, similar to the strategies taken by the field of
xenotransplantation. The ability to genetically modify ES
cells is a great advantage and could be used to overcome
both the directed differentiation/selection hurdle as well
as the immune response hurdle.
Xenotransplantation
In the ongoing search for a reliable source of tissue to
replace lost cells, tissues and organs, research in the area
of xenotransplantation (cross species transplantation) has
grown tremendously in the last 20 years. Overcoming the
immunologic hurdle of cross species transplantation as
well as the problem of cross-species pathogen infectivity,
i.e., xenozoonosis, are the scientific challenges facing the
field [78,79]. The ability to genetically modify species
such as the pig through transgenesis and nuclear transfer,
to express human genes and to mutate detrimental genes
expressed in pig cells [80-86] still holds promise for engi-
neered tissues and organs for human transplantation. The
production of galα1,3gal transferase null transgenic pigs
[84] represents a significant development towards elimi-
nating both hyperacute and acute vascular rejection andReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/102
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may lead to extended survival of pig organs in old world
primates, including humans, in combination with stand-
ard triple drug immunosuppressive therapy.
Interestingly, there have been a series of pig-to-human
xenotransplantation clinical experiments for the treat-
ment of diabetes [87,88] and FDA approved clinical trials
for the treatment of neurologic disorders using outbred
pig tissue [89-91]. Although there was some evidence of
cell engraftment in both indications [87,90], no efficacy
was established due to the transplant [87,89]. To date, a
Phase I clinical trial was completed using transgenically
engineered pig livers to detoxify the blood of fulminant
hepatic failure (FHF) patients via extracoporial perfusion
[92], however there is yet to be an FDA approved trans-
genic animal tissue for use in human transplantation.
Although the theoretical risk of xenozoonosis is a risk and
represents a significant psychosocial issue, several studies
investigating the possibility of cross species infectivity,
including a retrospective analysis of 160 human trans-
plant recipients exposed to porcine tissues have yet to
reveal transmission of porcine viruses to humans or pri-
mates in vivo [93-96]. The prospect of xenotransplanta-
tion is still relevant to solid organ and islet
transplantation and with FDA oversight, animal as well as
patient monitoring, the risks associated with xenozoono-
sis will be overcome.
The Future
The challenges associated with stem cell differentiation,
tissue engineering, and xenotransplantation are many-
fold in each of the respective fields, however one of the
biggest challenges beyond the science and biology is the
development of an FDA approved product from any of the
developmental areas discussed above. The regulatory
issues and points to consider documents are in the early
stages of development by the FDA in collaboration with
expert review panels and will continue to change as the
technology advances into clinical applications. The expe-
riences of Genzyme Biosurgery, Organogenesis, Diacrin,
Layton Biosciences, Titan Pharmaceuticals and other tis-
sue engineering companies will benefit the field as a
whole.
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